EVLO — Evelo Biosciences Share Price
- $0.00m
- $16.69m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | n/a | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | n/a | ||
Price to Sales | n/a | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | n/a | ||
Return on Equity | n/a | ||
Operating Margin | n/a |
Financial Summary
Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Evelo Biosciences, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing a class of oral medicines that act on immune cells in the small intestine with systemic effects. It has built a platform to discover and develop oral medicines, which target the small intestinal axis (SINTAX). Its product candidates are pharmaceutical preparations of single strains of microbes or their extracellular vesicles (EVs). Its product candidate, EDP1815, is an investigational oral biologic being developed for the treatment of inflammatory diseases. EDP1815 is in clinical development for both psoriasis, driven largely by Th17 inflammation, and atopic dermatitis, driven by TH2 inflammation. EDP2939 is an investigational oral biologic consisting of EVs that it is developing for the potential treatment of inflammatory diseases. EDP1867 is a non-live pharmaceutical preparation of a single strain of Veillonella parvula, isolated from the ileum of a human donor.
Directors
- David Epstein CHM (59)
- Balkrishan Gill PRE (56)
- Luca Scavo CFO (54)
- Mark Bodmer CSO (64)
- Daniel Char GCN (60)
- Duncan McHale OTH (54)
- Jonathan Zung OTH (56)
- Iain Mcinnes DRC
- Juan Andres IND (56)
- Lord Ara Darzi IND (60)
- John Hohneker IND
- Julie Mchugh IND (56)
- Theodose Melas-Kyriazi IND (61)
- David Perry IND (53)
- Nancy Simonian IND (60)
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- May 6th, 2014
- Public Since
- May 9th, 2018
- No. of Shareholders
- 26
- No. of Employees
- 66
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Pink Sheets on Nasdaq
- Shares in Issue
- 18,930,960
![Blurred out image of a map](https://www.stockopedia.com/assets/conversion/images/maps_placeholder.jpg)
- Address
- 124 WASHINGTON STREET, SUITE 101, FOXBORO, 02035
- Web
- https://evelobio.com/
- Phone
- +1 6175770300
- Auditors
- Ernst & Young LLP
Upcoming Events for EVLO
Q2 2024 Evelo Biosciences Inc Earnings Release
Q3 2024 Evelo Biosciences Inc Earnings Release
Similar to EVLO
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
As of Today at 20:34 UTC, shares in Evelo Biosciences are trading at $0.06. This share price information is delayed by 15 minutes.
Shares in Evelo Biosciences last closed at $0.06 and the price had moved by -96.67% over the past 365 days. In terms of relative price strength the Evelo Biosciences share price has underperformed the S&P500 Index by -97.21% over the past year.
The overall consensus recommendation for Evelo Biosciences is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Evelo Biosciences does not currently pay a dividend.
Evelo Biosciences does not currently pay a dividend.
Evelo Biosciences does not currently pay a dividend.
To buy shares in Evelo Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.06, shares in Evelo Biosciences had a market capitalisation of $1.14m.
Here are the trading details for Evelo Biosciences:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: EVLO
Based on an overall assessment of its quality, value and momentum Evelo Biosciences is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Evelo Biosciences is $10.00. That is 16566.67% above the last closing price of $0.06.
Analysts covering Evelo Biosciences currently have a consensus Earnings Per Share (EPS) forecast of -$6.70 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Evelo Biosciences. Over the past six months, its share price has outperformed the S&P500 Index by +46.85%.
As of the last closing price of $0.06, shares in Evelo Biosciences were trading -96.26% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Evelo Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.06.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Evelo Biosciences' management team is headed by:
- David Epstein - CHM
- Balkrishan Gill - PRE
- Luca Scavo - CFO
- Mark Bodmer - CSO
- Daniel Char - GCN
- Duncan McHale - OTH
- Jonathan Zung - OTH
- Iain Mcinnes - DRC
- Juan Andres - IND
- Lord Ara Darzi - IND
- John Hohneker - IND
- Julie Mchugh - IND
- Theodose Melas-Kyriazi - IND
- David Perry - IND
- Nancy Simonian - IND